Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Institutional Investor Sentiment Is 1.23

July 27, 2018 - By Catherine Diaz

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Logo

Sentiment for Rigel Pharmaceuticals Inc (NASDAQ:RIGL)

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) institutional sentiment decreased to 1.23 in 2018 Q1. Its down -0.83, from 2.06 in 2017Q4. The ratio fall, as 49 investment professionals increased or opened new stock positions, while 40 reduced and sold their stock positions in Rigel Pharmaceuticals Inc. The investment professionals in our partner’s database now hold: 126.59 million shares, down from 127.13 million shares in 2017Q4. Also, the number of investment professionals holding Rigel Pharmaceuticals Inc in their top 10 stock positions decreased from 1 to 0 for a decrease of 1. Sold All: 13 Reduced: 27 Increased: 35 New Position: 14.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company has market cap of $472.75 million. The companyÂ’s clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It currently has negative earnings. It is also developing two oncology product candidates, which are in Phase I and Phase II.

The stock decreased 2.69% or $0.08 during the last trading session, reaching $2.89. About 1.37M shares traded. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has risen 61.57% since July 27, 2017 and is uptrending. It has outperformed by 49.00% the S&P500.

Analysts await Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report earnings on August, 7. They expect $-0.16 EPS, 0.00 % or $0.00 from last year’s $-0.16 per share. After $-0.17 actual EPS reported by Rigel Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -5.88 % EPS growth.

Dafna Capital Management Llc holds 1.55% of its portfolio in Rigel Pharmaceuticals, Inc. for 901,933 shares. Rhenman & Partners Asset Management Ab owns 1.62 million shares or 0.71% of their US portfolio. Moreover, Nea Management Company Llc has 0.51% invested in the company for 3.24 million shares. The Maryland-based Rock Springs Capital Management Lp has invested 0.39% in the stock. J. Goldman & Co Lp, a New York-based fund reported 832,500 shares.

Since January 1, 0001, it had 0 buys, and 2 sales for $34,482 activity.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Ratings Coverage

Ratings analysis reveals 100% of Rigel’s analysts are positive. Out of 5 Wall Street analysts rating Rigel, 5 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $500 while the high is $10. The stock’s average target of $7.88 is 172.66% above today’s ($2.89) share price. RIGL was included in 13 notes of analysts from February 2, 2018. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, March 7. Cantor Fitzgerald maintained Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) on Tuesday, April 17 with “Buy” rating. The firm has “Buy” rating given on Tuesday, May 1 by Cantor Fitzgerald. BMO Capital Markets maintained the stock with “Outperform” rating in Wednesday, May 2 report. On Friday, February 2 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, April 18. Cantor Fitzgerald maintained the stock with “Buy” rating in Tuesday, March 6 report. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) earned “Buy” rating by H.C. Wainwright on Wednesday, May 2. H.C. Wainwright maintained Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) on Tuesday, April 3 with “Buy” rating. The rating was maintained by BMO Capital Markets on Wednesday, April 18 with “Outperform”.

Another recent and important Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) news was published by Nasdaq.com which published an article titled: “Recent Analysis Shows Synopsys, Rigel Pharmaceuticals, Fate Therapeutics, Philip Morris International, Sally Beauty …” on July 27, 2018.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.